Is Cryoport, Inc. (CYRX) a Buy, Sell, or Hold?
NASDAQ : CYRX
Cryoport, Inc. — News
$16.24 USD
$0.53 (3.37%)
- Volume
- 934.52K
- Average Volume
- 814.7K
- Market Capitalization
- $818.53M
- P/E Ratio
- 11.36
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $16.89
- Year Low
- $6.69
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.09
| Source | Headline |
|---|---|
|
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310). prnewswire.com - 2026-06-25 08:00:00 |
|
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-05 01:53:22 |
|
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago. zacks.com - 2026-05-04 18:50:27 |
|
Cryoport Reports First Quarter 2026 Financial Results
First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026 Company raises full-year revenue guidance to $192 million - $196 million NASHVILLE, Tenn., May 4, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its first quarter (Q1) of 2026. prnewswire.com - 2026-05-04 16:05:00 |
